Population pharmacokinetic modeling and simulation to support qualification of pyridoxic acid as endogenous biomarker of OAT1/3 renal transporters

被引:20
作者
Ahmad, Amais [1 ]
Ogungbenro, Kayode [1 ]
Kunze, Annett [2 ]
Jacobs, Frank [2 ]
Snoeys, Jan [2 ]
Rostami-Hodjegan, Amin [1 ,3 ]
Galetin, Aleksandra [1 ]
机构
[1] Univ Manchester, Sch Hlth Sci, Ctr Appl Pharmacokinet Res, Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England
[2] Janssen Pharmaceut Co, DMPK, Beerse, Belgium
[3] Simcyp Ltd, Sheffield, S Yorkshire, England
关键词
ORGANIC ANION TRANSPORTER; DRUG-DRUG INTERACTIONS; PREDICTION; IDENTIFICATION; CLEARANCE; PLASMA; PROBE; OAT3;
D O I
10.1002/psp4.12610
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Renal clearance of many drugs is mediated by renal organic anion transporters OAT1/3 and inhibition of these transporters may lead to drug-drug interactions (DDIs). Pyridoxic acid (PDA) and homovanillic acid (HVA) were indicated as potential biomarkers of OAT1/3. The objective of this study was to develop a population pharmacokinetic model for PDA and HVA to support biomarker qualification. Simultaneous fitting of biomarker plasma and urine data in the presence and absence of potent OAT1/3 inhibitor (probenecid, 500 mg every 6 h) was performed. The impact of study design (multiple vs. single dose of OAT1/3 inhibitor) and ability to detect interactions in the presence of weak/moderate OAT1/3 inhibitors was investigated, together with corresponding power calculations. The population models developed successfully described biomarker baseline and PDA/HVA OAT1/3-mediated interaction data. No prominent effect of circadian rhythm on PDA and HVA individual baseline levels was evident. Renal elimination contributed greater than 80% to total clearance of both endogenous biomarkers investigated. Estimated probenecid unbound in vivo OAT inhibitory constant was up to 6.4-fold lower than in vitro values obtained with PDA as a probe. The PDA model was successfully verified against independent literature reported datasets. No significant difference in power of DDI detection was found between multiple and single dose study design when using the same total daily dose of 2000 mg probenecid. Model-based simulations and power calculations confirmed sensitivity and robustness of plasma PDA data to identify weak, moderate, and strong OAT1/3 inhibitors in an adequately powered clinical study to support optimal design of prospective clinical OAT1/3 interaction studies.
引用
收藏
页码:467 / 477
页数:11
相关论文
共 35 条
[1]  
[Anonymous], 2020, Guidance for Industry
[2]   Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects [J].
Asaumi, Ryuta ;
Toshimoto, Kota ;
Tobe, Yoshifusa ;
Hashizume, Kenta ;
Nunoya, Ken-ichi ;
Imawaka, Haruo ;
Lee, Wooin ;
Sugiyama, Yuichi .
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2018, 7 (03) :186-196
[3]   Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I [J].
Barnett, Shelby ;
Ogungbenro, Kayode ;
Menochet, Karelle ;
Shen, Hong ;
Humphreys, W. Griffith ;
Galetin, Aleksandra .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2019, 368 (01) :125-135
[4]   Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1B-Mediated Drug-Drug Interactions Using Population Pharmacokinetic Modeling and Simulation [J].
Barnett, Shelby ;
Ogungbenro, Kayode ;
Menochet, Karelle ;
Shen, Hong ;
Lai, Yurong ;
Humphreys, W. Griffith ;
Galetin, Aleksandra .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (03) :564-574
[5]  
Beal S. L., 2009, NONMEM User's Guides (1989-2009)
[6]   DAISY:: A new software tool to test global identifiability of biological and physiological systems [J].
Bellu, Giuseppina ;
Saccomani, Maria Pia ;
Audoly, Stefania ;
D'Angio, Leontina .
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, 2007, 88 (01) :52-61
[7]  
Brodin, 2015, TRANSPORTERS DRUG DE
[8]   Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium [J].
Chu, Xiaoyan ;
Liao, Mingxiang ;
Shen, Hong ;
Yoshida, Kenta ;
Zur, Arik A. ;
Arya, Vikram ;
Galetin, Aleksandra ;
Giacomini, Kathleen M. ;
Hanna, Imad ;
Kusuhara, Hiroyuki ;
Lai, Yurong ;
Rodrigues, David ;
Sugiyama, Yuichi ;
Zamek-Gliszczynski, Maciej J. ;
Zhang, Lei .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (05) :836-864
[9]   Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions [J].
Chu, Xiaoyan ;
Chan, Grace Hoyee ;
Evers, Raymond .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (09) :2357-2367
[10]   Cyclosporine Inhibition of Hepatic and Intestinal CYP3A4, Uptake and Efflux Transporters: Application of PBPK Modeling in the Assessment of Drug-Drug Interaction Potential [J].
Gertz, Michael ;
Cartwright, Catherine M. ;
Hobbs, Michael J. ;
Kenworthy, Kathryn E. ;
Rowland, Malcolm ;
Houston, J. Brian ;
Galetin, Aleksandra .
PHARMACEUTICAL RESEARCH, 2013, 30 (03) :761-780